WO2022157314A1 - Acide hyaluronique à utiliser sur la peau - Google Patents

Acide hyaluronique à utiliser sur la peau Download PDF

Info

Publication number
WO2022157314A1
WO2022157314A1 PCT/EP2022/051351 EP2022051351W WO2022157314A1 WO 2022157314 A1 WO2022157314 A1 WO 2022157314A1 EP 2022051351 W EP2022051351 W EP 2022051351W WO 2022157314 A1 WO2022157314 A1 WO 2022157314A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
colony counts
incubation
acnes
epidermidis
Prior art date
Application number
PCT/EP2022/051351
Other languages
English (en)
Inventor
Volker Rosenberger
Riccardo SFRISO
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of WO2022157314A1 publication Critical patent/WO2022157314A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin

Definitions

  • the present invention relates to the topical use of certain hyaluronic acids as topical prebiotic, i.e. for balancing microbiota of skin by selectively increasing the growth of at least one beneficial over at least one harmful microbe in said microbiota, in particular in sebaceous skin.
  • Skin is the outermost protective covering of living beings and is the largest organ in the body.
  • One of the main functions of the skin is to form a physical barrier (commonly called the skin barrier) that protects the body from external factors.
  • skin prevents entry of harmful or potentially harmful chemicals and/ or microbes such as e.g. bacteria, fungi and viruses, into the body thereby preventing adverse effects that may be caused thereof.
  • Dysbiosis in the skin microbiome may furthermore contribute to a weakening or even a breakdown of the skin barrier.
  • Such compromised skin then allows for an increased penetration of exogenous substances, such as e.g. bacteria, fungi, polluting agents, irritant agents or allergenic substances, which in turn may cause (further) mild to severe adverse health effects such as skin irritation, allergic reactions or even infections.
  • exogenous substances such as e.g. bacteria, fungi, polluting agents, irritant agents or allergenic substances, which in turn may cause (further) mild to severe adverse health effects such as skin irritation, allergic reactions or even infections.
  • microbiome balancing i.e. fostering and/ or maintaining a healthy balance of the skin microbes of a certain skin microbiota to keep the skin in healthy and infection free condition, is often desired by people.
  • Microbiome balancing may be achieved e.g. by a reduction or elimination of unwanted bacteria on the skin by application of topical compositions comprising one or more antimicrobial compound.
  • antimicrobial compounds do not work in a selective manner.
  • said compounds generally do not selectively act only against the unwanted bacteria but often also lead to the removal of the beneficial ones, which in turn may lead to dysbiosis and thus a weakened skin barrier and adverse skin reactions which is not desired.
  • Microbiome balancing may however also be achieved by way of utilizing a prebiotic that promotes growth of desired microbes over undesired microbes in a certain microbiota, preferably while not significantly altering or even reducing the overall population of microbes. Said microbiome balancing is considered as microbiome friendly.
  • microbiome friendly ingredients i.e. ingredients which, next to fulfilling their envisaged beneficial role in the respective cosmetic composition are further able to maintain and/ or even foster a healthy skin microbiome, and are thus able to prevent skin dysbiosis and accordingly any adverse effects potentially resulting thereof.
  • certain hyaluronic acids which are widely used in cosmetic compositions for hydration of skin are particularly microbiome friendly. Furthermore, it has been found that they provide microbiome balancing by way of acting as a selective prebiotic, i.e. by fostering the growth of S. epidermidis over P. acnes in the microbiome of sebaceous skin while not significantly altering the overall amount of the microbes. Said effect can be used for microbiome balancing in skin regions where a ratio of S. epidermidis to P. acnes of ⁇ 1 is generally desirable such as e.g. facial skin.
  • Said selective prebiotic effect can be used to maintain skin healthy, i.e. used in beauty routines for youthful and healthy skin and thus be non-therapeutic, i.e. cosmetic.
  • the present invention relates to a topical non-therapeutic (i.e. cosmetic) use of hyaluronic acid having a molecular weight selected in the range of 0.1 to 2.0 MDa as a selective prebiotic, in particular when applied to sebaceous skin.
  • the prebiotic effect as defined herein can also be used for microbiome balancing when applied to the skin, in particular for microbiome balancing of the microbes of sebaceous skin, most preferably as present in facial and body skin.
  • the present invention also relates to the hyaluronic acid according to the present invention for use in maintaining the balance of a healthy skin microbiome comprising at least the microbes S. epidermidis and P. acnes, preferably in the concomitant presence of at least one, preferably all microbes selected from the group of S. hominis, S. capitis, S. mitis, C. simulans and M. globosa when applied to the skin, such as in particular to the skin microbiome of sebaceous skin, most preferably of sebaceous facial and/ or body skin.
  • the present invention also relates to the hyaluronic acid according to the present invention for the use in the prevention of skin dysbiosis in a subject, wherein the skin dysbiosis is associated with a decreased number of S. epidermidis and an over-colonization by P. acnes.
  • the invention also relates to the hyaluronic acid according to the present invention for use in counteracting the weakening of the skin barrier caused by a disbalance of the skin microbiome as well as in preventing or reducing the penetration of exogeneous molecules and/or microorganisms following such a weakening such as in particular S. aureus.
  • the present invention also relates to the hyaluronic acid according to the present invention for use in a method of prophylactically treating skin dysbiosis in a subject, wherein said skin dysbiosis is associated with decreased levels of S. epidermidis and increased levels of P. acnes, and wherein said hyaluronic acid has prebiotic effects by selectively increasing the skin levels of said S. epidermidis over said P. acnes.
  • the prebiotic effect of the hyaluronic acid according to the present invention is characterized by increasing the growth (and share) of S. epidermidis in a skin microbiome while concomitantly reducing the growth (and share) of P.
  • the acnes preferably in the presence of at least one, preferably all microbes selected from the group consisting of S. hominis, S. capitis, S. mitis, C. simulans and M. globosa.
  • the overall population of microbes in the microbiome is not reduced or more preferably even increased, most preferably, however by no more than 100%, more preferably by no more than 75%, most preferably by no more than 50%, such as by no more than 40% after incubation at 37°C for 4h, compared to to, i.e. before incubation (but in the presence of said hyaluronic acid).
  • other hyaluronic acids in contrast to the hyaluronic acid according to the present invention lead to a significant reduction of the overall population, which is not desirable according in the use according to the present invention.
  • the ratio of S. epidermidis to P. acnes after the treatment is at least 1 , more preferably at least 1 .5, most preferably at least 2 (i.e. after the incubation at 37°C for 4h). Even more advantageously the ratio is selected in the range from 1 to 5, preferably in the range from 1 .5 to 4, such as most preferably in the range of 2 to 3. It is furthermore preferred, that in all embodiments of the present invention the ratio of S. epidermidis to P. acnes before the treatment, is less than 1 , more preferably less than 0.75, most preferably less than 0.5.
  • the noun ‘prebiotic’ is used in this document as equivalent ’a compound having a prebiotic effect'.
  • skin microbiome or microbes of sebaceous skin refers to a microbiome which comprises especially two or more, preferably all of Propionibacterium acnes (P. acnes), Staphylococcus epidermidis (S. epidermidis), Staphylococcus hominis (S. hominis), Staphylococcus capitis (S. capitis), Streptococcus mitis (S. mitis), Corynebacterium simulans (C. simulans) and Malassezia globosa (M. globosa).
  • P. acnes Propionibacterium acnes
  • S. epidermidis Staphylococcus epidermidis
  • Staphylococcus hominis S. hominis
  • Staphylococcus capitis S. capitis
  • Streptococcus mitis S. mitis
  • Corynebacterium simulans C. simulans
  • Malassezia globosa M. globo
  • the skin microbiome is characterized in that the ratio of S. Epidermis to P. acnes before the use/ treatment according to the present invention is ⁇ 1 , more preferably ⁇ 0.75, most preferably ⁇ 0.5.
  • microbiome balancing refers to maintaining the skin in healthy and infection free condition. Said microbiome balancing is achieved by selectively reducing the microbial count of at least one genus of harmful microbes or of at least one genus of microbes that exhibits abnormal growth (P. acnes) in favor of selectively increasing microbial count of at least one genus of beneficial microbes (S. epidermidis). Preferably, said microbiome balancing takes place such, that the ratio of S. Epidermis to P. acnes after the use/ treatment according to the present invention is > 1 , preferably > 1 .2, most preferably > 1 .25, such as in particular > 2.
  • the microbiome balancing takes place in a skin microbiota, wherein before the use/ treatment as disclosed herein the ratio of S. epidermidis to P. acnes before the treatment, is less than 1 , more preferably less than 0.75, most preferably less than 0.5.
  • microbiome balancing can e.g. be assessed by measuring the microbiome friendliness according to standard methods in the art (MyMicrobiome Standard 18.10) and is preferably characterised by not significantly altering the shares of the individual microbes in a skin microbiome after incubation at 37°C for 4h, except for the intended ones, here S. epidermidis and P. acnes.
  • MyMicrobiome Standard 18.10 is preferably characterised by not significantly altering the shares of the individual microbes in a skin microbiome after incubation at 37°C for 4h, except for the intended ones, here S. epidermidis and P. acnes.
  • a particular advantageous microbiome balancing according to the present invention is depicted in Figure 2.
  • the microbiome balancing according to the present invention is a balancing of the microbes of P. acnes and S. epidermidis, more preferably in the presence of at least one, most preferably all microbes selected from the group consisting of Staphylococcus hominis (S. horn inis), Staphylococcus capitis (S. capitis), Streptococcus mitis (S. mitis), Corynebacterium simulans (C. simulans ) and Malassezia globosa (M. globosa).
  • share refers to the share of each (individual) microbe with regard to the total number of microbes in a microbial co-culture in % (i.e. with regard to at least two, preferably all sebaceous skin microbes as defined herein). Said share is calculated using the colony count of the respective (individual) microbe divided by the sum of the colony counts of all microbes of the respective microbiota * 100%.
  • colonyforming unit (cfu) per milliliter Any 'count(s)’ or ‘colony count(s)’ of microbe(s) is given in this document as colonyforming unit (cfu) per milliliter.
  • skin as used in this document, is meant to include the external surface of mammals, especially humans and includes the skin and the scalp.
  • Preferred skin in all embodiments of the present invention is however, facial and body skin such as most preferably facial skin.
  • prevention refers to lessening the risk of developing a dysbiosis associated with a decreased number of S. epidermidis and an overcolonization by P. acnes and consequently any diseases associated therewith and/ or the administration to people in risk of developing a dysbiosis associated with a decreased number of S. epidermidis and an over-colonization by P. acnes.
  • the exogenous molecules can be in particular irritant substances (hygiene products, solvents, etc.) or allergenic substances (perfumes, house dust, microbial agents).
  • hyaluronic acid covers the basic unit of hyaluronic acid which includes the smallest fraction of hyaluronic acid comprising a disaccharide dimer, namely D-glucuronic acid and N-acetylglucosamine as well as linear polymers of said disaccharides, which are composed of D-glucuronic acid and N-acetyl-D-glucosamine, linked via alternating (3-(1 — >4) and (3-(1 — >3) glycosidic bonds.
  • hyaluronic acid as used herein also comprises hyaluronic acid salts, and in particular the alkali metals such as the sodium salt and the potassium salt, most preferably the sodium salts. Such salts are known as sodium hyaluronate.
  • the hyaluronic acid according to the present invention is characterized in having a molecular weight selected in the range of 0.1 to 2.0 MDa.
  • hyaluronic acid having a molecular weight selected in the range of 0.5 to 1.75 MDa, more preferably in the range of 0.75 to 1 .5 MDa such as in particular in the range of 1 to 1 .3 MDa is used as such hyaluronic acid leads to a particular pronounced reduction in the growth and share of P. acnes while increasing the growth and share of S. epidermidis, while being particular microbiome friendly, i.e. without significantly affecting the shares of the other microbes contained in the microbiome, as outlined in figure 2.
  • hyaluronic acid in all embodiments of the present invention is sodium hyaluronate (CAS 9067-32-7), which is e.g. commercial available from Givaudan under the tradenames Cristalhyal 2.2 (MW 1 .8 - 2.2 MDa), Cristalhyal (MW 1 - 1.4 MDa) and Cristalhyal 1.0 (MW 700 - 1000 kDa) or from Evonik under the tradename Hyacare (MW 800 kDa) or from DSM Nutritional Products Ltd under the tradename HYA-ACTTM M (1 to 1 .3 MDa) or HYA-ACTTM S (200 to 400kDa).
  • Cristalhyal 2.2 MW 1 .8 - 2.2 MDa
  • Cristalhyal MW 1 - 1.4 MDa
  • Cristalhyal 1.0 MW 700 - 1000 kDa
  • Hyacare MW 800 kDa
  • HYA-ACTTM M (1 to 1 .3 MDa
  • the molecular weight of the hyaluronic acid according to the present invention is determined via calculation using the intrinsic viscosity determined by capillary type viscometer at 25°C according to standard methods in the art.
  • the hyaluronic acids according to the present invention can also be defined by their intrinsic viscosity determined by using a capillary type viscometer at 25 °C, which, in all embodiments of the present invention, is preferably selected in the range 4 to 30 dl/g, more preferably in the range of 10 to 25 dl/g, most preferably in the range from 15 to 25 g/dl.
  • the prebiotic effect respectively the microbiome balancing according to the present invention is most preferably characterized by reducing the growth and decreasing the share of P. acnes and promoting the growth and increasing the share of S. epidermidis, in the concomitant presence of at least one, preferably all microbes selected from the groups consisting of S. hominis, S. capitis, S. mitis, C. simulans and M. globosa.
  • said prebiotic effect is most preferably characterized in that the change in the individual share of S. epidermidis and P. acnes in the concomitant presence of at least one microbe M(i) selected from the group consisting of S. hominis, S. capitis, S. mitis, C. simulans and M. globosa, preferably in the presence of all microbes M(i) is
  • CPAo represents the colony counts of P. acnes directly after inoculation
  • CSE 0 represents the colony counts of S. epidermidis directly after inoculation
  • CSHo represents the colony counts of S. hominis directly after inoculation
  • CSCo represents the colony counts of S. capitis directly after inoculation
  • CSMo represents the colony counts of S. mitis directly after inoculation
  • CCSo represents the colony counts of C. simulans directly after inoculation
  • CMG 0 represents the colony counts of M. globosa directly after inoculation
  • CPA 4 represents the colony counts of P. acnes after 4 hours of incubation
  • CSE 4 represents the colony counts of S. epidermidis after 4 hours of incubation
  • CSH4 represents the colony counts of S. hominis after 4 hours of incubation
  • CSC4 represents the colony counts of S. capitis after 4 hours of incubation
  • CSM 4 represents the colony counts of S. mitis after 4 hours of incubation
  • CCS 4 represents the colony counts of C. simulans after 4 hours of incubation
  • CMG4 represents the colony counts of M. globosa after 4 hours of incubation; wherein the incubation is at 37°C.
  • said change in the individual share of S. epidermidis and P. acnes is
  • CM(i )0 represents the colony counts of the respective microbe M(i) directly after inoculation
  • CM ( i)4 represents the colony counts of the respective microbe M(i) after 4 hours of incubation wherein the incubation is at 37°C.
  • the present invention also relates to the use of the hyaluronic acid according to the present invention with all the definitions and preferences as given herein as a selective prebiotic for S. epidermidis, in particular in the concomitant presence of at least one, preferably all the microbes M(i) consisting of the group of S. hominis, S. capitis, S. mitis, C. simulans and M. globosa, even more in particular to balance the skin microbiome of sebaceous skin and foster skin health.
  • the term ‘use as a selective prebiotic’ as used herein in particular also refers to a method for treating dysbiosis of the skin of a subject, comprising a) providing an area of skin having a microbiota and a state of dysbiosis b) providing a topical composition comprising a hyaluronic acid according to the present invention, and c) applying said topical composition to the area of skin, and d) changing the microbiota of the skin by reducing the number of microorganisms promoting dysbiosis, such as in particular P. acnes and increasing the number of organisms promoting eubiosis such as in particular S. epidermidis- and changing the state of dysbiosis to a state of eubiosis.
  • the hyaluronic acid according to the present invention or a composition comprising said hyaluronic acid, respectively is in one advantageous embodiment applied on healthy skin and maintains or improves the aesthetic aspect of said skin; in said embodiments of the present invention all uses and methods are cosmetic and non-therapeutical.
  • a preferred aspect of the invention relates to a non-therapeutical, cosmetic method of maintaining a healthy skin microbiome in particular of sebaceous skin, said method comprising the step of topically applying a cosmetic composition comprising a hyaluronic acid with all the definitions and preferences as given herein to a subject and optionally appreciating the effect. It is well understood that all definitions and preferences as outlined herein also apply to the method.
  • the hyaluronic acid is preferably applied to the skin incorporated into a cosmetic or dermatological composition.
  • the amount of the hyaluronic acid in the cosmetic composition is preferably selected in the range from 0.001 to 6.0 wt.-%, preferably 0.01 to 5.0 wt.-%, more preferably 0.1 to 3.0 wt.-%, based on the total weight of the cosmetic composition. Further suitable ranges encompass 0.5 to 3 wt.-% or 1 to 2.5 wt.-%, based on the total weight of the cosmetic composition.
  • cosmetic composition refers to cosmetic compositions as defined under the heading "Kosmetika” in Rompp Lexikon Chemie, 10th edition 1997, Georg Thieme Verlag Stuttgart, New York as well as to cosmetic compositions as disclosed in A. Domsch, "Cosmetic Compositions", Verlag fur chemische Industrie (ed. H. Ziolkowsky), 4 th edition, 1992.
  • compositions according to the present invention are in particular compositions intended to be topically applied to mammalian keratinous tissue such as in particular to human skin or the human scalp.
  • cosmetic or dermatological compositions are topical cosmetic or dermatological compositions.
  • the cosmetic or dermatological composition may be a leave-on or a rinse off cosmetic composition, and includes any product applied to a human body primarily for improving appearance, cleansing, odor control or general aesthetics.
  • the cosmetic or dermatological composition of the present invention are leave-on compositions.
  • compositions according to the present invention preferably further comprise a physiologically acceptable medium, that is to say a medium compatible with keratinous substances, such as the skin, mucosa, and keratinous fibers.
  • physiologically acceptable medium is a cosmetically respectively dermatologically acceptable carrier.
  • cosmetically respectively dermatologically acceptable carrier refers to all carriers and/or excipients and/or diluents conventionally used in cosmetic compositions or dermatological or pharmaceutical compositions.
  • the cosmetic or dermatological composition may comprise further ingredients.
  • Such ingredients are particularly surfactants, emulsifiers, thickeners, and oils.
  • surfactants, emulsifiers, thickeners, and oils are well known to a person skilled in the art.
  • the cosmetic or dermatological compositions according to the invention are in the form of a suspension or dispersion in solvents or fatty substances, or alternatively in the form of an emulsion or micro emulsion (in particular of O/W- or W/O- type), PIT-emulsion, nano emulsion, multiple emulsion (e. g. O/W/O- or W/O/W-type), pickering emulsion, hydrogel, lipogel, one- or multiphase solution or vesicular dispersion.
  • an emulsion or micro emulsion in particular of O/W- or W/O- type
  • PIT-emulsion nano emulsion
  • multiple emulsion e. g. O/W/O- or W/O/W-type
  • pickering emulsion hydrogel, lipogel, one- or multiphase solution or vesicular dispersion.
  • the cosmetic or dermatological compositions in accordance with the invention can be in the form of a liquid, lotion, a thickened lotion, a gel, a cream, a milk, an ointment or a paste.
  • the cosmetic or dermatological compositions according to the invention generally have a pH in the range from 3-10, preferably in the range from pH of 3-8, most preferred in the range from pH 3.5-7.5.
  • the pH is adjusted by methods known to a person skilled in the art, e.g. by using an acid such as a hydroxy acid including glycolic acid, lactic acid, malic acid, citric acid and tartaric acid or a base such as e.g. sodium or potassium hydroxide or ammonium hydroxide as well as mixtures thereof.
  • the cosmetic or dermatological compositions according to the present invention are in particular skin care preparations, functional preparations and/or hair care preparations such as most in particularly skin or hair care preparations.
  • Examples of skin care preparations are, in particular, light protective preparations (sun care preparations), anti-ageing preparations, preparations for the treatment of photoageing, body oils, body lotions, body gels, treatment creams, skin protection ointments, moisturizing preparations such as moisturizing gels or moisturizing sprays, face and/or body moisturizers, as well as skin lightening preparations.
  • light protective preparations unsun care preparations
  • anti-ageing preparations preparations for the treatment of photoageing
  • body oils body lotions, body gels, treatment creams, skin protection ointments
  • moisturizing preparations such as moisturizing gels or moisturizing sprays
  • face and/or body moisturizers as well as skin lightening preparations.
  • Examples of functional preparations are cosmetic compositions containing active ingredients such as hormone preparations, vitamin preparations, vegetable extract preparations, anti-ageing preparations, and/or antimicrobial (antibacterial or antifungal) preparations without being limited thereto.
  • hair care preparations which are suitable according to the invention and which may be mentioned are shampoos, hair conditioners (also referred to as hair rinses), hairdressing compositions, hair tonics, hair regenerating compositions, hair lotions, water wave lotions, hair sprays, hair creams, hair gels, hair oils, hair pomades or hair brilliantines. Accordingly, these are always preparations which are applied to the hair and the scalp for a shorter or longer time depending on the actual purpose for which they are used.
  • the cosmetic or dermatological compositions according to the present invention are emulsions and/or gels. Even more preferably, the cosmetic or dermatological compositions are emulsions which contain an oily phase and an aqueous phase such as in particular O/W, W/O, Si/W, W/Si, O/W/O, W/O/W multiple or a pickering emulsions.
  • the amount of the oily phase (i.e. the phase containing all oils and fats including the polar oils) present in such emulsions is preferably at least 10 wt.-%, such as in the range from 10 to 60 wt.-%, preferably in the range from 15 to 50 wt.-%, most preferably in the range from 15 to 40 wt.-%, based on the total weight of the cosmetic or dermatological composition.
  • the amount of the aqueous phase present in such emulsions is preferably at least 20 wt.-%, such as in the range from 20 to 90 wt.-%, preferably in the range from 30 to 80 wt.-%, most preferably in the range from 30 to 70 wt.-%, based on the total weight of the cosmetic or dermatological composition.
  • the hyaluronic acid according to the present invention may have a particular beneficial effect on the skin microbiome, when combined with further skin active ingredients.
  • Particularly preferred skin active ingredients according to the present invention are plant-derived carbohydrate compounds such as monosaccharides, disaccharides, oligosaccharides or polysaccharides, preferably fructans and galactans, as well as saccharide isomerates and polyols, particularly glycerol, sugar alcohols e.g. maltitol, sorbitol, xylitol, erythritol and isomalt, vitamins such as niacinamide and peptides, such as tripeptides such as in particular SYNO-HYCAN from DSM Nutritional Products Ltd as well as mixtures thereof.
  • plant-derived carbohydrate compounds such as monosaccharides, disaccharides, oligosaccharides or polysaccharides, preferably fructans and galactans, as well as saccharide isomerates and polyols, particularly glycerol, sugar alcohols e.g. maltitol, sorbitol, xy
  • Saccharide isomerate is for example commercially available under trade name Pentavitin® from DSM Nutritional Products AG, Switzerland.
  • Niacinamide is for example commercially available under trade name Niacinamid PC from DSM Nutritional Products AG, Switzerland.
  • monosaccharide examples include glucose, fructose, galactose and mixtures thereof.
  • disaccharides include sucrose, maltose, lactose and mixtures thereof.
  • oligosaccharides include fructo-oligosaccharides, gluco-oligosaccharide and mixtures thereof.
  • Fructans are a category of carbohydrate consisting of fructooligosaccharides (FOS) and inulins, while galactans consist of galactooligosaccharides (GOS). Further preferred prebiotics are resistant starch, pectin, beta-glucans, and xylooligosaccharides.
  • niacinamide is niacinamide
  • compositions comprising the hyaluronic acid according to the present invention and at least one skin active ingredient, preferably saccharide isomerate and/or niacinamide, as described above are used to balance the microbiome of human skin and/or hair, particularly of the scalp or the scalp hair, with all the definitions and preferences as given herein.
  • skin active ingredient preferably saccharide isomerate and/or niacinamide
  • Assay 5 mL of TSB (Tryptic Say Broth) to which 500 pL of 1 wt.-% of the respective hyaluronic acid [(f) HYA-ACTTM M (HA-M). MW 1-1.3 MDa; (2) HYA-ACTTM S (HAS). MW 200-400 kDa; (Ref.1) HYA-ACTTM XS (HA-XS): MW 37-56KDa] in PBS (Phosphate-buffered saline) have been added.
  • TSB Tryptic Say Broth
  • Table 1 shows the counts of colony (CFU/ml) and shares of the respective microbes after at to and t4, i.e. 4 hours of incubation at 37°C. All shares have been rounded.
  • Table 1 Figure 1 illustrates the share (i.e. distribution) of the respective microbe of sebaceous skin (i.e. rcn/wo respectively rcn/iw) for the results (1) directly after inoculation (to) (figure 1 a), respectively after 4 hours of incubation (t 4h ) (figure 1 b) at 37°C by means of a pie diagram illustrating the prebiotic effect of the hyaluronic acid according to the present invention reflected by an increase in the share in S. epidermidis and a reduction in the share P. acnes.
  • Table 2 shows the counts of colony (CFU/ml) and shares of the respective microbes after at to and t 4 , i.e. 4 hours of incubation at 37°C. All shares have been rounded.
  • Figure 2 illustrates the share (i.e. distribution) of the respective microbe of sebaceous skin (i.e. r C M(i>o respectively ICMW) for the results (2) directly after inoculation (to) (figure 2a), respectively after 4 hours of incubation (t 4 ) (figure 2b) at 37°C by means of a pie diagram illustrating the prebiotic effect of the hyaluronic acid according to the present invention reflected by an increase in the share in S. Epidermidis and a reduction in the share P. acnes in the skin microbiome of sebaceous skin, while not significantly the shares of the other microbes.
  • Table 3 shows the counts of colony (CFU/ml) of the respective microbes after 4 hours of incubation at 37°C of (1), (2) and (RefT) versus Control (i.e. no hyaluronic acid).
  • Table 4 shows the counts of colony (CFU/ml) and shares of the respective microbes after at to and t 4 , i.e. 4 hours of incubation at 37°C. All shares have been rounded.
  • Table 4 Figure 3 illustrates the share (i.e. distribution) of the respective microbe of sebaceous skin (i.e. r C M(i>o respectively r C M(i>4) for the reference results (Ref.T) directly after inoculation (to) (figure 3a), respectively after 4 hours of incubation (t 4 h) (figure 3b) at 37°C by means of a pie diagram, illustrating a concomitant increase in the share of S. epidermidis and P. acnes in the skin microbiome of sebaceous skin.
  • mice friendliness Table 5 shows the results of the microbiome friendliness assay performed with 1 % solutions of the respective hyaluronic acid in PBS at MyMicrobiome (MyMicrobiome Standard 18.10). As can be retrieved from the table below, the hyaluronic acids according to the present invention are significantly superior compared to a small molecular weight hyaluronic acid. Table 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de certains acides hyaluroniques en tant que prébiotique topique, en particulier dans la peau sébacée.
PCT/EP2022/051351 2021-01-22 2022-01-21 Acide hyaluronique à utiliser sur la peau WO2022157314A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21152936 2021-01-22
EP21152936.7 2021-01-22

Publications (1)

Publication Number Publication Date
WO2022157314A1 true WO2022157314A1 (fr) 2022-07-28

Family

ID=74205735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/051351 WO2022157314A1 (fr) 2021-01-22 2022-01-21 Acide hyaluronique à utiliser sur la peau

Country Status (1)

Country Link
WO (1) WO2022157314A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117860649A (zh) * 2024-03-08 2024-04-12 珠海金肽生物科技有限公司 一种调节皮肤微生态和修复肌肤屏障的组合物及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144613A1 (fr) * 2006-06-13 2007-12-21 Sinclair Pharmaceuticals Limited Composition antimicrobienne
WO2008009956A1 (fr) * 2006-07-20 2008-01-24 Oraldent Limited Combinaisons pour compositions orales, leur préparation et leur utilisation
WO2009124266A2 (fr) * 2008-04-04 2009-10-08 University Of Utah Research Foundation Ethers de glycoaminoglycosan semi-synthétiques alkylés et leurs procédés de fabrication et d’utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144613A1 (fr) * 2006-06-13 2007-12-21 Sinclair Pharmaceuticals Limited Composition antimicrobienne
WO2008009956A1 (fr) * 2006-07-20 2008-01-24 Oraldent Limited Combinaisons pour compositions orales, leur préparation et leur utilisation
WO2009124266A2 (fr) * 2008-04-04 2009-10-08 University Of Utah Research Foundation Ethers de glycoaminoglycosan semi-synthétiques alkylés et leurs procédés de fabrication et d’utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Rompp Lexikon Chemie", 1997, GEORG THIEME VERLAG, article "Kosmetika"
A. DOMSCH: "Cosmetic Compositions", 1992, VERLAG FUR CHEMISCHE INDUSTRIE
DE GRANDI R ET AL: "Effects of topical 5% hyaluronic acid and a bacterial-wall-derived glycoproteins and peptide glycans (GPPG) complex on facial microbioma in subjects with seborrheic dermatitis", JOURNAL OF THE DERMATOLOGY NURSES' ASSOCIATION 20200301 LIPPINCOTT WILLIAMS AND WILKINS NLD, vol. 12, no. 2, 1 March 2020 (2020-03-01), XP055812737, ISSN: 1945-760X *
PIRNAZAR PAYMAN ET AL: "Bacteriostatic effects of hyaluronic acid", JOURNAL OF PERIODONTOLOGY, AMERICAN ACADEMY OF PERIODONTOLOGY, US, vol. 70, no. 4, 1 April 1999 (1999-04-01), pages 370 - 374, XP008162701, ISSN: 0022-3492, DOI: 10.1902/JOP.1999.70.4.370 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117860649A (zh) * 2024-03-08 2024-04-12 珠海金肽生物科技有限公司 一种调节皮肤微生态和修复肌肤屏障的组合物及应用

Similar Documents

Publication Publication Date Title
JPH10513165A (ja) 抗接着性の有効成分
US10792258B2 (en) Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US20230301885A1 (en) Novel use
US20140271881A1 (en) Antiseptic composition
JP2002053428A (ja) 皮膚外用剤
WO2022157314A1 (fr) Acide hyaluronique à utiliser sur la peau
EP3723714B1 (fr) Mononitrate de propanediol monoacetate
US8486459B2 (en) Bulbine frutescens extract
WO2022157307A1 (fr) Acide hyaluronique en tant qu'agent antimicrobien destiné à être utilisé sur la peau
JP3658626B2 (ja) 化粧品および医薬部外品
US11324680B2 (en) Topical compositions
JP7187740B2 (ja) 新規の使用
US10933002B2 (en) Preservation booster
KR102630903B1 (ko) 신규 용도
IT201600096125A1 (it) Complesso e composizioni per il trattamento di affezioni oculari e cutanee
EP4104814A1 (fr) Nouvelle utilisation de la vitamine b12
WO2019007791A1 (fr) Compositions topiques
JP5586130B2 (ja) 抗菌性組成物及び化粧料
US12083085B2 (en) Antiseptic, antiseborrheic, exfoliating composition to remove or prevent acne
JP2004307385A (ja) 抗菌剤
US20240058252A1 (en) Cosmetic method and composition based on short-chain fructooligosaccharides and a native starch
JP4831960B2 (ja) 頭皮頭髪用組成物
CN117835960A (zh) 抗坏血酸与人乳寡糖的组合物
CN117813075A (zh) 用于化妆品和药物组合物的防腐剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22702210

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22702210

Country of ref document: EP

Kind code of ref document: A1